Nuclear Medicine and Molecular Imaging

  • 제40권2호
  • /
  • Pages.132-140
  • /
  • 2006
  • /
  • 1869-3474(pISSN)
  • /
  • 1869-3482(eISSN)
대한핵의학회 (The Korean Society of Nuclear Medicine)
권호 표지

갑상샘암의 방사성요오드 치료의 최신 지견

Recent Advances in Radioiodine Therapy for Thyroid Cancer

  • 배상균 (인제대학교 의과대학 핵의학교실)
  • Bae, Sang-Kyun (Department of Nuclear Medicine, Inje University College of Medicine)
  • 발행 : 2006.04.29
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Well-differentiated thyroid cancer is the most common endocrine malignancy with an increasing incidence. Most patients with well-differentiated thyroid caner have a favorable prognosis with high survival rate. While surgery and radioiodine therapy is sufficient treatment for the majority of patients with differentiated thyroid cancer, a minority of these patients experiences progressive, life-threatening growth and metastatic spread of the disease. Because there is no prospective controlled study to evaluate the differences of management of thyroid cancer, it is hard to choose the best treatment option. And there are still lots of controversies about the management of this disease, such as surgical extent, proper use of radioiodine for remnant ablation and therapy, use of rhTSH instead of withdrawal of thyroid hormone, long-term follow-up strategy, thyroglobulin as a tumor marker, etc. In this review, recent data related to these conflicting issues and recent advances in diagnosis, radioiodine therapy and long-term monitoring of well-differentiated thyroid cancer are summarized.

키워드

참고문헌

  1. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28 https://doi.org/10.1016/0002-9343(94)90321-2
  2. Hong SW. Radioiodine therapy for differentiated thyroid cancer. Korean J Nucl Med 2000;34:265-75
  3. Song YK. Treatment of differentiated thyroid cancer. Korean J Nucl Med 2002;36:77-97
  4. Bae SK. Radioiodine therapy of thyroid disease. Korean J Nucl Med 2001;35:11-8p
  5. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-41 https://doi.org/10.1089/thy.2006.16.109
  6. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050-7
  7. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, et al. Papillary thyroid carcinoma managed at the mayo clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26:879-85 https://doi.org/10.1007/s00268-002-6612-1
  8. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-24 https://doi.org/10.1210/jcem-71-2-414
  9. Byar DP, Green SB, Dor P, Williams ED, Colon J, van Gilse HA, et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid cancer cooperative group. Eur J Cancer 1979;15:1033-41 https://doi.org/10.1016/0014-2964(79)90291-3
  10. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104:947-53
  11. Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995;118:1131-6 https://doi.org/10.1016/S0039-6060(05)80124-2
  12. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, et al. Prospective multicenter study of thyroid carcinoma treatment: Initial analysis of staging and outcome. National thyroid cancer treatment cooperative study registry group. Cancer 1998;83:1012-21 https://doi.org/10.1002/(SICI)1097-0142(19980901)83:5<1012::AID-CNCR28>3.0.CO;2-9
  13. Thyroid. In: Green FL, Page DL, Fleming ID, et al., eds. AJCC cancer staging manual. Sixth edition. New York: Springer, 2002
  14. Soh EY, Clark OH. Surgical considerations and approach to thyroid cancer. Endocrinol Metab Clin North Am 1996;25:115-39 https://doi.org/10.1016/S0889-8529(05)70315-7
  15. Grebe SK, Hay ID. Thyroid cancer nodal metastases: Biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996;5:43-63
  16. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. And german thyroid cancer study group. An American college of surgeons commission on cancer patient care evaluation study. Cancer 2000;89:202-17 https://doi.org/10.1002/1097-0142(20000701)89:1<202::AID-CNCR27>3.0.CO;2-A
  17. Goss M, D'Amico S, Mobiglia A, Sargiotto A, Deandrea M. Surgical approach to cervical lymph node metastasis in differentiated thyroid cancer. Tumori 2002;88:S47-8
  18. Shah MD, Hall FT, Eski SJ, Witterick IJ, Walfish PG, Freeman JL. Clinical course of thyroid carcinoma after neck dissection. Laryngoscope 2003;113:2102-7 https://doi.org/10.1097/00005537-200312000-00008
  19. Wong JB, Kaplan MM, Meyer KB, Pauker SG. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metab Clin North Am 1990;19:741-60
  20. Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American thyroid association. Arch Intern Med 1996;156:2165-72 https://doi.org/10.1001/archinte.156.19.2165
  21. Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: Insights gained from the mayo clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc 2002;113:241-60
  22. Logue JP, Tsang RW, Brierley JD, Simpson WJ. Radioiodine ablation of residual tissue in thyroid cancer: Relationship between administered activity, neck uptake and outcome. Br J Radiol 1994;67:1127-31 https://doi.org/10.1259/0007-1285-67-803-1127
  23. Robbins RJ, Schlumberger MJ. The evolving role of $^{131}$I for the treatment of differentiated thyroid carcinoma. J Nucl Med 2005;46 Suppl 1:28S-37S
  24. Ringel MD, Ladenson PW. Controversies in the follow-up and management of well-differentiated thyroid cancer. Endocr Relat Cancer 2004;11:97-116 https://doi.org/10.1677/erc.0.0110097
  25. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937-41 https://doi.org/10.1056/NEJM198310203091601
  26. Maxon HR. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med 1999;43:313-23
  27. Fatourechi V, Hay ID, Mullan BP, Wiseman GA, Eghbali-Fatourechi GZ, Thorson LM, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 2000;10:573-7 https://doi.org/10.1089/thy.2000.10.573
  28. Sherman SI, Tielens ET, Sostre S, Wharam MD, Jr., Ladenson PW. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994;78:629-34 https://doi.org/10.1210/jc.78.3.629
  29. Souza Rosario PW, Barroso AL, Rezende LL, Padrao EL, Fagundes TA, Penna GC, et al. Post I-131 therapy scanning in patients with thyroid carcinoma metastases: An unnecessary cost or a relevant contribution? Clin Nucl Med 2004;29:795-8 https://doi.org/10.1097/00003072-200412000-00005
  30. Ronga G, Filesi M, Montesano T, Di Nicola AD, Pace C, Travascio L, et al. Lung metastases from differentiated thyroid carcinoma. A 40 years' experience. Q J Nucl Med Mol Imaging 2004;48:12-9
  31. Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 2001;86:1568-73 https://doi.org/10.1210/jc.86.4.1568
  32. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid 2003;13:265-71 https://doi.org/10.1089/105072503321582060
  33. Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 2005;46:261-6
  34. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638-44 https://doi.org/10.1038/sj.bjc.6601319
  35. Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR, Vassilopoulou-Sellin R. The development of breast carcinoma in women with thyroid carcinoma. Cancer 2001;92:225-31 https://doi.org/10.1002/1097-0142(20010715)92:2<225::AID-CNCR1313>3.0.CO;2-B
  36. Campos-Pastor MM, Munoz-Torres M, Escobar-Jimenez F, Ruiz de Almodovar M, Jodar Gimeno E. Bone mass in females with different thyroid disorders: Influence of menopausal status. Bone Miner 1993;21:1-8 https://doi.org/10.1016/S0169-6009(08)80115-8
  37. Florkowski CM, Brownlie BE, Elliot JR, Ayling EM, Turner JG. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma. N Z Med J 1993;106:443-4
  38. Gouveia CH, Jorgetti V, Bianco AC. Effects of thyroid hormone administration and estrogen deficiency on bone mass of female rats. J Bone Miner Res 1997;12:2098-107 https://doi.org/10.1359/jbmr.1997.12.12.2098
  39. Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly men. Arch Intern Med 1995;155:2005-7 https://doi.org/10.1001/archinte.155.18.2005
  40. Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Ferguson L, et al. Randomized trial of pamidronate in patients with thyroid cancer: Bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 1998;83:2324-30 https://doi.org/10.1210/jc.83.7.2324
  41. Rosen HN, Moses AC, Gundberg C, Kung VT, Seyedin SM, Chen T, et al. Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans. J Clin Endocrinol Metab 1993;77:664-9 https://doi.org/10.1210/jc.77.3.664
  42. Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen. Jama 1994;271:1245-9 https://doi.org/10.1001/jama.271.16.1245
  43. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888-96 https://doi.org/10.1056/NEJM199709253371304
  44. Ladenson PW. Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma. Semin Nucl Med 2000;30:98-106
  45. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-85 https://doi.org/10.1210/jc.84.11.3877
  46. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86:619-25 https://doi.org/10.1210/jc.86.2.619
  47. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, et al. RhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: A comprehensive review. Endocr Relat Cancer 2005;12:49-64 https://doi.org/10.1677/erc.1.00830
  48. Robbins RJ, Tuttle RM, Sonenberg M, Shaha A, Sharaf R, Robbins H, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001;11:865-9 https://doi.org/10.1089/105072501316973127
  49. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002;87:3242-7 https://doi.org/10.1210/jc.87.7.3242
  50. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, et al. Ablation of thyroid residues with 30 mCi $^{131}$I: A comparison in thyroid cancer patients prepared with recombinant human tsh or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002;87:4063-8 https://doi.org/10.1210/jc.2001-011918
  51. Mariotti S, Barbesino G, Caturegli P, Marino M, Manetti L, Pacini F, et al. Assay of thyroglobulin in serum with thyroglobulin autoantibodies: An unobtainable goal? J Clin Endocrinol Metab 1995;80:468-72 https://doi.org/10.1210/jc.80.2.468
  52. Spencer CA, Wang CC. Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls. Endocrinol Metab Clin North Am 1995;24:841-63
  53. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88: 1433-41 https://doi.org/10.1210/jc.2002-021702
  54. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 1999;9:435-41 https://doi.org/10.1089/thy.1999.9.435
  55. Park YJ. The measurement of serum thyroglobulin levels. J Kor Soc Endocrinol 2004;19:120-6
  56. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. 1994;4:49-54 https://doi.org/10.1089/thy.1994.4.49
  57. Hurley JR. Management of thyroid cancer: Radioiodine ablation, 'stunning,' and treatment of thyroglobulin-positive, $^{131}$I scan-negative patients. Endocr Pract 2000;6:401-6 https://doi.org/10.4158/EP.6.5.401
  58. Grunwald F, Briele B, Biersack HJ. Non-$^{131}$I -scintigraphy in the treatment and follow-up of thyroid cancer. Single-photon-emitters or FDG-PET? Q J Nucl Med 1999;43:195-206
  59. Mandel SJ, Shankar LK, Benard F, Yamamoto A, Alavi A. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2001;26:6-9 https://doi.org/10.1097/00003072-200101000-00002
  60. Siddiqi A, Foley RR, Britton KE, Sibtain A, Plowman PN, Grossman AB, et al. The role of $^{123}$I -diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to $^{131}$I -scanning: Avoidance of negative therapeutic uptake due to stunning. Clin Endocrinol 2001;55:515-21 https://doi.org/10.1046/j.1365-2265.2001.01376.x
  61. de Geus-Oei LF, Oei HY, Hennemann G, Krenning EP. Sensitivity of $^{123}$I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2002;29:768-74 https://doi.org/10.1007/s00259-002-0781-x
  62. Clark OH, Hoelting T. Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans. Thyroid 1994;4:501-5 https://doi.org/10.1089/thy.1994.4.501
  63. Chung J-K. Management of recurrent thyroid carcinoma with negative diagnostic radioiodine whole-body scan. Korean J Nucl Med 2001; 35:117-24
  64. Yeo JS. The role of PET in thyroid cancer. Korean J Nucl Med 2002;36:147-54
  65. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-72
  66. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative $^{131}$I scan. J Nucl Med 2001;42:71-6
  67. Larson SM, Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol 2002;37:169-74 https://doi.org/10.1016/S0037-198X(02)80035-9
  68. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P. Recombinant human thyrotropin stimulation of fluoro-d-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89:91-5 https://doi.org/10.1210/jc.2003-031027
  69. Petrich T, Borner AR, Otto D, Hofmann M, Knapp WH. Influence of rhTSH on $^{18}$F-fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002;29:641-7 https://doi.org/10.1007/s00259-001-0745-6
  70. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80:1488-92 https://doi.org/10.1210/jc.80.5.1488
  71. McDougall IR. $^{131}$I treatment of $^{131}$I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: What is being treated? Thyroid 1997;7:669-72 https://doi.org/10.1089/thy.1997.7.669
  72. Mazzaferri EL. Treating high thyroglobulin with radioiodine: A magic bullet or a shot in the dark? J Clin Endocrinol Metab 1995;80:1485-7 https://doi.org/10.1210/jc.80.5.1485
  73. Fatourechi V, Hay ID. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: Including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med 2000;30:107-14 https://doi.org/10.1053/nm.2000.4600
  74. Schlumberger M, Mancusi F, Baudin E, Pacini F. $^{131}$I therapy for elevated thyroglobulin levels. Thyroid 1997;7:273-6 https://doi.org/10.1089/thy.1997.7.273
  75. Van Herle AJ, Agatep ML, Padua DN, 3rd, Totanes TL, Canlapan DV, Van Herle HM, et al. Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro. J Clin Endocrinol Metab 1990;71:755-63 https://doi.org/10.1210/jcem-71-3-755
  76. Spitzweg C, Morris JC. Gene therapy for thyroid cancer: Current status and future prospects. Thyroid 2004;14:424-34 https://doi.org/10.1089/105072504323150732
  77. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:458-60 https://doi.org/10.1038/379458a0
  78. Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, et al. Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun 1996;226:339-45 https://doi.org/10.1006/bbrc.1996.1358
  79. Smit JW, Shroder-van der Elst JP, Karperien M, Que I, van der Pluijm G, Goslings B, et al. Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hnis defective human thyroid carcinoma cell line. Thyroid 2000;10:939-43 https://doi.org/10.1089/thy.2000.10.939
  80. Smit JW, Schroder-van der Elst JP, Karperien M, Que I, Stokkel M, van der Heide D, et al. Iodide kinetics and experimental $^{131}$I therapy in a xenotransplanted human sodium-iodide symporter- transfected human follicular thyroid carcinoma cell line. J Clin Endocrinol Metab 2002;87:1247-53 https://doi.org/10.1210/jc.87.3.1247
  81. Petrich T, Knapp WH, Potter E. Functional activity of human sodium/iodide symporter in tumor cell lines. Nuklearmedizin 2003;42:15-8 https://doi.org/10.1055/s-0038-1623900
  82. Carlin S, Mairs RJ, Welsh P, Zalutsky MR. Sodium-iodide symporter (NIS)-mediated accumulation of [$^{211}$At]astatide in nis-transfected human cancer cells. Nucl Med Biol 2002;29:729-39 https://doi.org/10.1016/S0969-8051(02)00332-3
  83. Dadachova E, Bouzahzah B, Zuckier LS, Pestell RG. Rhenium-188 as an alternative to iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol 2002;29:13-8 https://doi.org/10.1016/S0969-8051(01)00279-7
  84. Petrich T, Helmeke HJ, Meyer GJ, Knapp WH, Potter E. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter. Eur J Nucl Med Mol Imaging 2002;29:842-54 https://doi.org/10.1007/s00259-002-0784-7
  85. Cengic N, Baker CH, Schutz M, Goke B, Morris JC, Spitzweg C. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 2005;90:4457-64 https://doi.org/10.1210/jc.2004-2140